Transforming personalised medicine with leading microbiome science

Microbiotica identifies gut bacteria linked to phenotype with unprecedented precision in order to discover and develop live bacterial therapeutics and biomarkers


Microbiotica was launched in December 2016 with the aim of creating a global leader to exploit the leading microbiome science built at the Wellcome Trust Sanger Institute. The company retains a close association with the Sanger Institute and its founders and is based at the Wellcome Genome Campus, Cambridge UK.

The Microbiome

The human body is host to trillions of microbes, comprising several hundred species per person residing mainly in the gastrointestinal tract. They are generally in a symbiotic relationship, impart protective functions to the gut, and regulate immunological, metabolic and neuronal functions throughout the body. Disruptions to the microbiome are implicated in a host of disorders, for example IBD, IBS, metabolic disease, cancer and Parkinson’s, and it is now clear that gut microbiota regulate the response to cancer immunotherapies. Thus the microbiome represents a major new opportunity in the discovery of medicines and biomarkers. The biggest barrier to this has been the inability to precisely identify a patient’s bacteria and then to undertake functional studies in order to understand the biology.


The Microbiotica platform is based on world leading tools developed at the Wellcome Trust Sanger Institute that unblock the barriers to discovery. These are founded on a unique capability to culture, characterise and phenotype the majority of a patient’s gut bacteria, enabling precise association of bacteria to function for the first time. They also include the leading microbiota culture collection and reference genome database which provide resources for precise metagenomic analysis and functional studies, and humanised in vitro and in vivo models of disease. Using these tools Microbiotica starts programs with deep analysis of samples from clinical trials and progresses medicines and biomarkers through lab testing back into the clinic.


Microbiotica has programs in IBD, immune-oncology and Clostridium difficile, developing medicines and biomarkers based on microbiota. These programs start with deep metagenomic and culture-based analysis of patient samples linked to phenotype before testing of candidate bacteria in advanced human in vitro and in vivo models. The company’s C. difficile defined live bacterial therapeutic asset will be used to validate our manufacturing and delivery technologies.


Latest News
Microbiotica relocates to Chesterford Research Park, Cambridge

Cambridge, UK, 19 November 2019: Chesterford Research Park and Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announce that Microbiotica is...

Microbiotica Appoints Thomas Lynch as Independent Non-Executive Chairman

Cambridge, UK, 25 September 2019 – Microbiotica, announces the appointment of Thomas Lynch as the new non-Executive Chairman of its Board, from 1 September 2019.

Microbiotica announced as a finalist in ‘Best Partnership Alliance’ category at Scrip Awards 2019

Cambridge, UK, 18 September 2019 – Microbiotica, a leading player in microbiome-based live therapeutics, has been selected as a finalist in the ‘Best Partnership...

Contact us